|
Dr. Louie is a board certified oncologist with more than 25 years of experience in pharmaceutical research and development. He was a vice president of medical affairs at Human Genome Sciences Inc. and a vice president of clinical research at Xoma Corporation. He also held leadership roles in clinical development at Pro-Neuron, Inc. Pro-Virus Inc., and Chiron Therapeutics. Dr. Louie was a director of cancer research at Bristol-Myers and consulted for Johnson & Johnson and Genta Incorporated. He was responsible for the successful effort to secure FDA approval for Proleukin IL-2, which is used for treatment of metastatic kidney cancer and for metastatic melanoma. Dr. Louie received a B. A. in Biology with honors from Haverford College, and an M.D. from New York University School of Medicine. He completed oncology fellowships at the National Cancer Institute and at Stanford University. | 